Antibody Ingredients TRIZ Cases

Replacing PVC with polyolefin elastomers prevents protein aggregation in anti-EGFRvIII infusions, ensuring high recovery rates for glioblastoma treatment.

Priming doses of anti-CD47 antibody prevent hemagglutination while eliminating ovarian cancer stem cells.

Segmented antibody structures with modified Fc regions inhibit tumor growth while avoiding unintended immune responses.

Targeting CD163 on M2 macrophages reduces immunosuppression and promotes T cell activation for cancer and fibrosis treatment.

Humanized anti-CD5 antibodies target CD5-positive cells to induce apoptosis, resolving the trade-off between therapeutic efficacy and immunodeficiency.

B7-H3 antibody-drug conjugates paired with PD-1 and CTLA-4 bispecific molecules utilize periodic dosing schedules to target cancer cells.

Anti-GPC3 antibody-drug conjugate overcomes weak antitumor efficacy of monoclonal antibodies by linking a cytotoxic drug to the targeting component.

Combining CHI3L1 inhibition with immune checkpoint blockade addresses low survival rates in lung cancer treatment.

Bispecific antibodies bind the beta-hairpin of HER3 and domain II of HER2 to block receptor dimerization.

A 177Lu-HH1 radioimmunoconjugate binds the CD37 antigen on tumor cells to deliver targeted cytotoxic radiation.

Anti-Tim-3 antibodies selectively block galectin-9 and phosphatidylserine interactions to restore anti-tumor immunity against cancers resistant to PD-1 therapy.

Antibodies 1G6-D7 and 5C4-D4 target extracellular Hsp90alpha to inhibit cancer cell motility, addressing limited efficacy of small molecule inhibitors.

Conjugating biotin to Fc domains exploits the neonatal Fc receptor recycling pathway to extend antibody serum half-life.

An isolated antibody binds Repulsive Guidance Molecule c to modulate hepcidin expression and regulate iron metabolism.

Antibodies bind specifically to BCMA on malignant B-cells, resolving the trade-off between targeting precision and therapeutic versatility.

Engineered interchain disulfide bonds in the pseudoFab moiety prevent heavy and light chain mispairing during multispecific antibody production.

Targeted antibodies block CD97 signaling to improve survival in glioblastoma and leukemia.

Antibody conjugates bind CD74 to deliver therapeutic payloads, reducing off-target effects in cancer treatment.

EphB3-specific antibodies inhibit cancer cell proliferation by inducing receptor phosphorylation, oligomerization, internalization, and degradation.

An anti-CD28 domain antibody antagonizes CD28 to inhibit T cell activation.

Autoantibodies against NaV1.5 channels diagnose Brugada syndrome by resolving genetic testing gaps where etiology remains unclear.

Disulfide bonds stabilize gpA33-CD3 diabodies against dissociation, resolving production complexity while ensuring functional half-life.

Specific heavy and light chain CDR sequences enable targeted depletion of tumor-resident regulatory T cells without blocking ligand binding to the receptor.

SK1 inhibitor modulates sphingosine-1-phosphate signaling to increase CD8+ T cell infiltration, improving therapeutic response while reducing liver toxicity.

Cytotoxic lipid nanoparticles conjugated to alphaCD163 antibodies deplete CD163+ tumor-associated macrophages.

Anti-NRP2 antibodies bind human neuropilin-2 polypeptides to modulate receptor-ligand interactions.

A segmented dosing regimen using anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates manages B-cell proliferative disorders.

Cilia-targeting nanoparticles deliver fenoldopam to primary cilia via dopamine receptor antibodies.

Co-formulations of anti-LAG3 and anti-PD-1 antibodies maintain biological activity through optimized pH and excipients.

A bispecific antibody binds TRAILR2 and CDH17 to induce apoptosis in cancer cells.

Anti-FcRn antibodies block neonatal Fc receptor recycling, reducing autoantibody levels and improving hemoglobin in warm autoimmune hemolytic anemia.

Modified CDR sequences enable specific binding to canine CD20, overcoming the inefficacy of human monoclonal antibodies in treating canine B-cell lymphoma.

HCMV-20 antibody binds human cytomegalovirus to neutralize infectivity, addressing inconsistent efficacy and side effects of existing antiviral drugs.

Linking TLR7 agonists to tyrosine kinase inhibitors forms conjugates that overcome drug resistance and synergize anti-tumor activity.

Bispecific antibodies bridge MUC16 on tumors with CD28 on T-cells, resolving systemic toxicity risks from broad immune activation.

Modified CD3 bispecific antibody variants stabilize binding affinity through targeted amino acid substitutions in variable regions.

Measuring AMH and inhibin B levels replaces complex semen analysis to accurately stratify patients for RANKL inhibitor therapy.

High-dose chimeric poliovirus combined with checkpoint inhibitors overcomes primary resistance and delays tumor growth.

Simultaneous binding of EGFR and cMET receptors prevents adaptive resistance mechanisms that emerge during monotherapy.

Optimized antibody CDR sequences increase binding affinity to SLAMF6, resolving the trade-off between treatment efficacy and manufacturing complexity.

A bispecific antibody molecule recruits transduced CD8+ T-cells to tumor cells via dual antigen binding domains.

Anti-SEZ6 antibody drug conjugates deliver topoisomerase 1 inhibitors to tumor cells via a chemical linker.

Modified human IgG4 antibodies use specific hinge mutations to achieve stable heterodimer formation.

Heavy chain antibodies target folate receptor alpha, reducing off-target effects on normal tissues.

Anti-ILT3 antibodies bind specifically to ILT3-expressing cells to induce targeted cell death in cancer treatments.